Trial Profile
Evaluate non-inferiority and persistence of the immune response of GSK Biologicals' meningococcal vaccine 134612 versus Meningitec or Mencevax ACWY in healthy subjects (1-10 years of age).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A C Y W-135 conjugate (Primary) ; Meningococcal vaccine group C conjugate; Meningococcal vaccine groups A C W-135 polysaccharide; Meningococcal vaccine groups A C Y W-135 polysaccharide
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors GlaxoSmithKline; GSK
- 27 Jul 2012 Actual end date May 2012 added as reported by ClinicalTrials.gov.
- 01 May 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 09 Feb 2010 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.